Opendata, web and dolomites

NOVITREP

Novel viral therapy through targeting DNA repair

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NOVITREP project word cloud

Explore the words cloud of the NOVITREP project. It provides you a very rough idea of what is the project "NOVITREP" about.

market    potently    human    born    company    replication    babies    threatening    viruses    viral    causing    individuals    zoonotic    proteins    ebola    plan    antiviral    ongoing    action    secure    host    strategy    foundation    cells    therapies    world    dna    prevent    virus    infectious    sweden    outbreaks    cell    erc    oxidative    repair    income    fever    relationship    grant    pathogenic    inhibitors    crimean    newly    ebov    zika    therapy    perform    therapeutics    zikv    exists    agency    hemorrhagic    western    treatments    congo    life    made    health    disturbs    natural    lesions    pose    mechanism    demonstrating    infected    business    suggesting    proof    explore    genecadd    drug    public    diseases    resistance    surprise    microcephaly    acquired    cancer    causal    internationally    potent    global    constant    power    networks    tool    ip    anti    reduce    outbreak    rna    discover    damage    prevented    genetic    optimize    cycle    epidemics    battle    cchfv    investigation    therapeutic    revealed   

Project "NOVITREP" data sheet

The following table provides information about the project.

Coordinator
KAROLINSKA INSTITUTET 

Organization address
address: Nobels Vag 5
city: STOCKHOLM
postcode: 17177
website: www.ki.se

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Total cost 150˙000 €
 EC max contribution 150˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2016-PoC
 Funding Scheme ERC-POC
 Starting year 2017
 Duration (year-month-day) from 2017-07-01   to  2018-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    KAROLINSKA INSTITUTET SE (STOCKHOLM) coordinator 139˙162.00
2    KAROLINSKA INSTITUTET INNOVATIONS AB SE (SOLNA) participant 10˙837.00

Map

Leaflet | Map data © OpenStreetMap contributors, CC-BY-SA, Imagery © Mapbox

 Project objective

Natural epidemics and outbreaks of emerging infectious diseases are a growing problem internationally. RNA viruses remain under constant attention due to the recent Zika virus (ZIKV) outbreak with potential causal relationship with microcephaly of newly born babies and Ebola virus (EBOV) and Crimean-Congo hemorrhagic fever virus (CCHFV) causing life threatening hemorrhagic fever, demonstrating how zoonotic viruses pose a major global health concern. There is an ongoing need to discover novel therapies to battle these pathogenic viruses given that no specific therapy exists. Developing new antiviral treatments by targeting host cell proteins needed in the viral life cycle is an emerging strategy to improve therapeutic power and reduce acquired drug resistance.

Based on the results from the ERC grant Genetic Networks as a tool for anti-Cancer Drug Development (GENECADD), we have developed potent inhibitors to DNA repair proteins that disturbs repair of oxidative DNA lesions. To our surprise, we observed, in collaboration with Public Health Agency of Sweden, that these inhibitors potently prevent ZIKV, EBOV and CCHFV viral replication in human cells, suggesting that these inhibitors may be used as antiviral therapeutics. Further investigation into the possible mechanism of action revealed that our inhibitors prevented the repair of oxidative damage to RNA.

Here, the overall aim is to (1) further develop and optimize our inhibitors as a novel antiviral target and demonstrate proof of concept, (2) explore and secure IP (3) develop a business plan and (4) perform a market analysis. The overall goal is to develop general antiviral treatments made available to virus-infected individuals through a public foundation in low-income areas or through a company in the Western world.

 Publications

year authors and title journal last update
List of publications.
2018 Torkild Visnes, Armando Cázares-Körner, Wenjing Hao, Olov Wallner, Geoffrey Masuyer, Olga Loseva, Oliver Mortusewicz, Elisée Wiita, Antonio Sarno, Aleksandr Manoilov, Juan Astorga-Wells, Ann-Sofie Jemth, Lang Pan, Kumar Sanjiv, Stella Karsten, Camilla Gokturk, Maurice Grube, Evert J. Homan, Bishoy M. F. Hanna, Cynthia B. J. Paulin, Therese Pham, Azita Rasti, Ulrika Warpman Berglund, Catharina von Nicolai, Carlos Benitez-Buelga, Tobias Koolmeister, Dag Ivanic, Petar Iliev, Martin Scobie, Hans E. Krokan, Pawel Baranczewski, Per Artursson, Mikael Altun, Annika Jenmalm Jensen, Christina Kalderén, Xueqing Ba, Roman A. Zubarev, Pål Stenmark, Istvan Boldogh, Thomas Helleday
Small-molecule inhibitor of OGG1 suppresses proinflammatory gene expression and inflammation
published pages: 834-839, ISSN: 0036-8075, DOI: 10.1126/science.aar8048
Science 362/6416 2019-09-04

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NOVITREP" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NOVITREP" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

E-DURA (2018)

Commercialization of novel soft neural interfaces

Read More  

PonD (2019)

Particles-on-Demand for Multiscale Fluid Dynamics

Read More  

Regen-membrane (2019)

Pulsed Electrophoretic Deposition to give Membranes for Regenerative Medicine

Read More